Literature DB >> 23784368

Capsule commentary on Shahinian et al.: Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

David F Penson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23784368      PMCID： PMC3797357          DOI： 10.1007/s11606-013-2513-2

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   5.128


× No keyword cloud information.
  4 in total

1.  Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo
Journal:  J Gen Intern Med       Date:  2013-05-14       Impact factor: 5.128

2.  A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.

Authors:  Laurence H Klotz; Irene Y McNeill; Marlene Kebabdjian; Liying Zhang; Joseph L Chin
Journal:  Eur Urol       Date:  2012-09-11       Impact factor: 20.096

3.  A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen
Journal:  J Natl Cancer Inst       Date:  2002-10-02       Impact factor: 13.506

4.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.